Futura Medical – MED3000 approved for Commercialisation in Saudi Arabia under the brand name Eroxon®
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology, today announces that its distribution partner Labatec Pharma (“Labatec”) has received regulatory approval for MED3000, Futura’s innovative topical, gel-based Erectile Dysfunction (“ED”) treatment, in the Kingdom of Saudi Arabia.
